Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · September 21, 2024

De-Escalation to Ticagrelor Monotherapy vs 12-Month DAPT in Patients With and Without Acute Coronary Syndrome

The Lancet

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials
Lancet 2024 Sep 07;404(10456)937-948, M Valgimigli, SJ Hong, F Gragnano, K Chalkou, A Franzone, BR da Costa, U Baber, BK Kim, Y Jang, SL Chen, GW Stone, JY Hahn, S Windecker, MC Gibson, YB Song, Z Ge, P Vranckx, S Mehta, HC Gwon, RD Lopes, GD Dangas, EP McFadden, DJ Angiolillo, S Leonardi, D Heg, P Calabrò, P Jüni, R Mehran, MK Hong

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading